IRIS
CECCHERINI SILBERSTEIN, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 70.830
AS - Asia 11.861
EU - Europa 9.463
SA - Sud America 1.774
Continente sconosciuto - Info sul continente non disponibili 1.354
AF - Africa 263
OC - Oceania 36
Totale 95.581
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 70.358
SG - Singapore 5.728
CN - Cina 2.003
IT - Italia 1.919
BR - Brasile 1.421
RU - Federazione Russa 1.329
DE - Germania 1.123
HK - Hong Kong 1.014
VN - Vietnam 916
SE - Svezia 816
UA - Ucraina 815
IE - Irlanda 800
BD - Bangladesh 707
FR - Francia 583
FI - Finlandia 509
GB - Regno Unito 481
PL - Polonia 449
KR - Corea 432
JP - Giappone 311
CA - Canada 240
IN - India 170
NL - Olanda 149
AR - Argentina 121
ID - Indonesia 119
AT - Austria 110
MX - Messico 109
ES - Italia 102
ZA - Sudafrica 74
TR - Turchia 64
BE - Belgio 62
EC - Ecuador 53
CZ - Repubblica Ceca 49
IQ - Iraq 48
CO - Colombia 46
PH - Filippine 45
PK - Pakistan 42
UZ - Uzbekistan 35
CL - Cile 33
JM - Giamaica 32
VE - Venezuela 30
CH - Svizzera 28
AU - Australia 27
ET - Etiopia 27
PY - Paraguay 27
MY - Malesia 26
KE - Kenya 23
MA - Marocco 23
AE - Emirati Arabi Uniti 22
PE - Perù 20
JO - Giordania 19
LT - Lituania 19
DZ - Algeria 18
CM - Camerun 17
HN - Honduras 17
RO - Romania 17
EG - Egitto 16
EU - Europa 16
IR - Iran 16
SA - Arabia Saudita 16
IL - Israele 15
KZ - Kazakistan 14
CR - Costa Rica 12
GR - Grecia 12
NP - Nepal 12
PT - Portogallo 12
TW - Taiwan 12
UY - Uruguay 12
NG - Nigeria 11
TN - Tunisia 11
DO - Repubblica Dominicana 10
TH - Thailandia 10
AL - Albania 9
BG - Bulgaria 9
KG - Kirghizistan 9
NZ - Nuova Zelanda 9
BO - Bolivia 8
DK - Danimarca 8
AO - Angola 7
AZ - Azerbaigian 7
BB - Barbados 7
HR - Croazia 7
HU - Ungheria 7
SC - Seychelles 7
GT - Guatemala 6
OM - Oman 6
PA - Panama 6
RS - Serbia 6
TT - Trinidad e Tobago 6
XK - ???statistics.table.value.countryCode.XK??? 6
CI - Costa d'Avorio 5
CY - Cipro 5
LB - Libano 5
LK - Sri Lanka 5
LV - Lettonia 5
NO - Norvegia 5
PR - Porto Rico 5
PS - Palestinian Territory 5
SV - El Salvador 5
A2 - ???statistics.table.value.countryCode.A2??? 4
DM - Dominica 4
Totale 94.167
Salva come PNG Salva come JPEG
Città #
Woodbridge 17.829
Wilmington 17.459
Houston 14.253
Singapore 3.085
Fairfield 2.207
Ashburn 1.818
San Jose 1.495
Chandler 1.376
Ann Arbor 1.360
Hong Kong 989
Seattle 897
Council Bluffs 860
Beijing 821
Cambridge 719
Dublin 694
Jacksonville 665
Rome 600
Santa Clara 539
Medford 494
New York 452
Los Angeles 403
Dearborn 368
Kraków 359
The Dalles 332
Helsinki 297
Ho Chi Minh City 293
Tokyo 277
Hanoi 232
Lawrence 230
Moscow 224
Buffalo 223
Milan 197
Munich 165
San Diego 157
São Paulo 144
Dallas 138
Lauterbourg 133
Menlo Park 125
Nuremberg 116
Orem 116
London 104
Chicago 103
Mülheim 103
Boardman 98
Phoenix 90
Jakarta 86
Zhengzhou 70
Montreal 66
Frankfurt am Main 65
North Bergen 64
San Francisco 64
Brooklyn 63
Brussels 59
Creede 59
Atlanta 58
Redondo Beach 56
Toronto 56
Denver 55
Vienna 55
Naples 51
Warsaw 51
Johannesburg 47
Chennai 46
Shanghai 44
Mexico City 43
Palo Alto 43
Rio de Janeiro 43
Falls Church 42
Guangzhou 42
Lappeenranta 42
Redwood City 42
Amsterdam 41
Columbus 40
Poplar 38
Boston 35
Cedarhurst 35
Nanjing 35
Stockholm 35
Colorado Springs 34
Mountain View 34
Da Nang 33
Haiphong 32
Verona 32
Belo Horizonte 31
University Park 30
Brno 29
Dong Ket 29
Manchester 29
Norwalk 29
Kunming 27
Washington 27
Bari 26
Brasília 24
Madrid 24
Tashkent 24
Engelhard 23
Hefei 23
Miami 23
Mumbai 23
Charlotte 22
Totale 75.918
Salva come PNG Salva come JPEG
Nome #
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test 602
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 580
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes 573
Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase 554
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 538
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 536
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev 536
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 535
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 530
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 517
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 516
Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes 514
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 513
Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso 512
Virologic correlates of adherence to antiretroviral medications and therapeutic failure 509
Understanding HIV compartments and reservoirs 501
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 496
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 495
HIV fitness and resistance as covariates associated with the appearance of mutations under antiretroviral treatment 491
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 491
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 491
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 489
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues 488
Novel drug resistance mutations in HIV: Recognition and clinical relevance 484
Effective program against mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso 483
Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029 478
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 478
Novelties in evaluation and monitoring of human immunodeficiency virus-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success? 477
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 476
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs 475
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 474
Characterization of novel HIV drug resistance mutations using clustering, multidimensional scaling and SVM-based feature ranking 471
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature 471
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 470
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients 468
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 467
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 466
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 465
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors 463
New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors 463
A boceprevir failure in a patient infected with HCV-genotype 1g: importance and limitations of virus genotyping prior to HCV protease inhibitor-based therapy 460
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 460
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 454
Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort 454
Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning 454
Incomplete APOBEC3G/F neutralization by HIV-1 Vif mutants facilitates the genetic evolution from CCR5 to CXCR4 usage 452
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 449
HIV fitness and resistance as covariates associated with the appearance of mutations under antiretroviral treatment 449
Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy 449
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin 448
Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage 448
Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study 448
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens 448
Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation 447
Molecular dynamics and free energy studies on the wild-type and mutated hiv-1 protease complexed with four approved drugs: Mechanism of binding and drug resistance 446
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 446
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. 445
Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria 445
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 445
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro 445
The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors 444
Gene transfer in astrocytes: comparison between different delivering methods and expression of the HIV-1 protein Nef 443
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 443
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure 442
Dynamics of NRTI resistance mutations during therapy interruption 442
The use of human immunodeficiency virus resistance tests in clinical practice 442
Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes 442
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 441
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 439
The role of Thr139 in the human immunodeficiency virus type 1 reverse transcriptase sensitivity to (+)-calanolide A 437
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 436
The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype 435
May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics 435
Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir 434
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 433
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 433
Molecular diversity of HIV in Albania 431
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 431
HIV-Infected Late Presenter Patients 430
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes 430
Genetic and Structural Analysis of HIV-1 Rev Responsive Element Related to V38A and T18A Enfuvirtide Resistance Mutations 430
The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs 428
Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages 427
Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors 427
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 425
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 425
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 423
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 423
Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages 422
HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design 421
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 421
Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district 421
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors 420
HIV-2 A-subtype gp125(C2-V3-C3) mutations and their association with CCR5 and CXCR4 tropism. 420
Key genetic elements in HIV-1 gp120 V1,V2 and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N terminus and HIV-1 antigenetic Potential 419
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 419
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation 419
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 419
Computational analysis of Human Immunodeficiency Virus (HIV) Type-1 reverse transcriptase crystallographic models based on significant conserved residues found in Highly Active Antiretroviral Therapy (HAART)-treated patients 418
Resistance to novel drug classes 418
Totale 46.216
Salva come PNG Salva come JPEG
Categoria #
all - tutte 252.328
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 252.328
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.865 0 221 199 148 120 230 183 126 564 242 150 682
2022/20233.815 419 295 194 447 351 793 270 354 313 43 240 96
2023/20241.502 226 44 90 58 120 255 71 61 57 207 34 279
2024/20258.670 280 1.700 929 481 251 544 1.029 420 791 514 863 868
2025/202615.821 1.261 586 1.441 1.427 1.411 647 1.995 1.985 1.730 1.386 1.000 952
2026/20271.702 929 773 0 0 0 0 0 0 0 0 0 0
Totale 95.581